WASHINGTON – Shares of Human Genome Sciences Inc. tumbled 10.9 percent Friday after FDA drug reviewers questioned whether the modest benefit of Benlysta (belimumab) in treating some lupus patients is worth the potential increased risk of death, infection or adverse neuropsychiatric effects, including suicide. (BioWorld Today)